tesamorelin cost: Frequently asked questions

Switch to compounded tesamorelin through a telehealth provider or licensed 503B facility. Insurance denial is standard for off-label tesamorelin use (visceral fat reduction, body composition, anti-aging). Fewer than 5% of non-HIV patients receive coverage. Compounded versions cost $200–$450 monthly, which is 85–95% less than branded Egrifta retail pricing. The peptide mechanism and amino acid sequence are identical; the cost difference reflects distribution channel and FDA approval status of the finished product, not peptide efficacy.

You'll pay out-of-pocket regardless of source. Branded Egrifta is FDA-approved only for HIV-associated lipodystrophy; all other uses are off-label and not covered by insurance. Compounded tesamorelin or research-grade peptide from suppliers like Real Peptides offers the same growth hormone-releasing mechanism at $200–$450 monthly. Clinical evidence shows tesamorelin reduces visceral adipose tissue by 15–18% over 26 weeks in non-HIV populations, but prescribers must document off-label use and patients assume full cost.

Reduce dose to 0.5–1mg daily for two weeks before re-escalating. Injection site reactions, transient hyperglycemia, and joint stiffness occur in 20–30% of patients during the first month at therapeutic dose. These effects resolve with slower titration and do not indicate peptide intolerance. Lowering initial dose also reduces monthly spend during the adjustment period. 1mg daily costs $100–$225 monthly from compounded sources versus $200–$450 at full therapeutic dose.

Switch to compounded tesamorelin from a licensed 503B facility. Most denials occur because the indication doesn't meet FDA-approved labeling (HIV-associated lipodystrophy only), making appeals unlikely to succeed unless you can provide imaging evidence of excess visceral adipose tissue and documented metabolic complications. Compounded versions cost $800–$1,200 monthly as cash-pay alternatives. Less than most Egrifta copays even with partial insurance coverage. Verify the compounding pharmacy holds active FDA 503B registration and provides Certificates of Analysis showing peptide purity above 98%.

Verify the source immediately. Legitimate compounded tesamorelin from licensed facilities rarely prices below $700 monthly because raw synthesis costs for pharmaceutical-grade peptides run $400–$600 per 60mg at bulk rates. Pricing under $500 suggests either: (1) research-grade peptides sold by non-pharmacy suppliers without medical oversight, (2) international sources shipping products that may face customs seizure, or (3) lyophilised powders of unknown purity that haven't undergone third-party testing. None of these channels guarantee sterility, correct amino acid sequencing, or absence of endotoxin contamination. The three quality factors that make prescription peptides safe for subcutaneous injection.

Ask your prescribing physician about maintenance dosing protocols. Some patients respond to 1mg daily dosing after an initial 8–12 week loading phase at 2mg daily. Effectively cutting monthly peptide costs in half. This approach requires monitoring IGF-1 levels and waist circumference measurements to confirm continued efficacy at the lower dose. Another cost-reduction strategy: optimise reconstitution technique to minimise peptide waste. Using bacteriostatic water at the correct volume (typically 2mL per 2mg vial) and drawing slowly with proper needle gauge reduces the 5–10% loss that occurs from peptide adhesion to vial walls and syringe dead space.